Equities research analysts forecast that Oxford Immunotec Global PLC (NASDAQ:OXFD) will announce $33.56 million in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for Oxford Immunotec Global’s earnings, with the highest sales estimate coming in at $33.74 million and the lowest estimate coming in at $33.39 million. Oxford Immunotec Global posted sales of $30.43 million in the same quarter last year, which suggests a positive year-over-year growth rate of 10.3%. The business is expected to announce its next quarterly earnings results on Tuesday, October 30th.
According to Zacks, analysts expect that Oxford Immunotec Global will report full year sales of $113.01 million for the current financial year, with estimates ranging from $112.82 million to $113.39 million. For the next financial year, analysts expect that the firm will report sales of $127.41 million, with estimates ranging from $125.28 million to $129.54 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for Oxford Immunotec Global.
Oxford Immunotec Global (NASDAQ:OXFD) last posted its quarterly earnings results on Tuesday, July 31st. The company reported ($0.25) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.25). Oxford Immunotec Global had a negative net margin of 23.41% and a negative return on equity of 39.85%. The business had revenue of $29.32 million during the quarter, compared to the consensus estimate of $28.58 million. During the same quarter last year, the firm posted ($0.74) EPS. Oxford Immunotec Global’s revenue was up 12.3% compared to the same quarter last year.
NASDAQ OXFD traded down $0.10 during mid-day trading on Wednesday, hitting $15.48. The company’s stock had a trading volume of 3,707 shares, compared to its average volume of 172,371. Oxford Immunotec Global has a twelve month low of $10.00 and a twelve month high of $19.19. The company has a current ratio of 5.39, a quick ratio of 4.86 and a debt-to-equity ratio of 0.41. The company has a market cap of $408.73 million, a P/E ratio of -11.38 and a beta of -0.21.
In other Oxford Immunotec Global news, CEO Peter Wrighton-Smith sold 86,100 shares of Oxford Immunotec Global stock in a transaction on Tuesday, September 25th. The shares were sold at an average price of $18.42, for a total transaction of $1,585,962.00. Following the transaction, the chief executive officer now directly owns 539,569 shares of the company’s stock, valued at approximately $9,938,860.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold a total of 146,100 shares of company stock worth $2,518,162 over the last ninety days. Insiders own 6.61% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of OXFD. Schwab Charles Investment Management Inc. boosted its holdings in Oxford Immunotec Global by 17.8% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 47,700 shares of the company’s stock worth $594,000 after acquiring an additional 7,200 shares during the last quarter. BlackRock Inc. raised its stake in shares of Oxford Immunotec Global by 6.9% during the 1st quarter. BlackRock Inc. now owns 1,162,510 shares of the company’s stock worth $14,474,000 after purchasing an additional 74,565 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Oxford Immunotec Global by 258.0% during the 1st quarter. JPMorgan Chase & Co. now owns 19,554 shares of the company’s stock worth $243,000 after purchasing an additional 14,092 shares during the period. New York State Common Retirement Fund raised its stake in shares of Oxford Immunotec Global by 11.0% during the 1st quarter. New York State Common Retirement Fund now owns 58,581 shares of the company’s stock worth $729,000 after purchasing an additional 5,800 shares during the period. Finally, Russell Investments Group Ltd. raised its stake in shares of Oxford Immunotec Global by 28.1% during the 1st quarter. Russell Investments Group Ltd. now owns 81,375 shares of the company’s stock worth $1,013,000 after purchasing an additional 17,850 shares during the period. 92.44% of the stock is currently owned by hedge funds and other institutional investors.
Oxford Immunotec Global Company Profile
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology.
Featured Article: Average Daily Trade Volume Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.